Placebo for Ubrogepant
Phase 3
AbbViePlacebo for Ubrogepant is one of 40 therapeutic programs targeting Migraine. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
102 competitors in Migraine
#DrugCompanyPhaseTrials
1Zonegran
AAzurity Pharmaceuticals
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Magnesium
SSpherium Biomed
Phase 3
Triptans
PfizerPhase 3
Aspirin /d
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
BAT7104
TevaPhase 3
Placebo for Ubrogepant
AbbViePhase 3
Tizanidine Hydrochloride
EElan Pharmaceuticals
Phase 3
Bayer Aspirin
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Placebo for Ubrogepant. EMBL-EBI & Wellcome Sanger Institute.
- [3]